Skye Bioscience, Inc. Common Stock (SKYE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has a cash flow conversion efficiency ratio of 14.320x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.12 Million) by net assets ($-497.31K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SKYE market cap for the company's overall valuation and market capitalisation.
Skye Bioscience, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Skye Bioscience, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore SKYE cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
North Arrow Minerals Inc
V:NAR
|
-0.011x |
|
Libero Copper Corp
V:LBC
|
-0.737x |
|
Rostra AG
F:3330
|
N/A |
|
Zinitix Co.Ltd
KQ:303030
|
-0.124x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
-0.202x |
|
XTL Biopharmaceuticals Ltd ADR
NASDAQ:XTLB
|
-0.369x |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual cash flow conversion efficiency of Skye Bioscience, Inc. Common Stock from 2012 to 2025. View SKYE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.02 Million | $-43.06 Million | -2.151x | -480.73% |
| 2024-12-31 | $68.15 Million | $-25.24 Million | -0.370x | -105.66% |
| 2023-12-31 | $-2.13 Million | $-13.95 Million | 6.545x | +54.48% |
| 2022-12-31 | $-3.01 Million | $-12.74 Million | 4.237x | +483.70% |
| 2021-12-31 | $5.86 Million | $-6.47 Million | -1.104x | +91.78% |
| 2020-12-31 | $450.79K | $-6.05 Million | -13.430x | -22.11% |
| 2019-12-31 | $548.06K | $-6.03 Million | -10.999x | -4440.97% |
| 2018-12-31 | $-15.56 Million | $-3.94 Million | 0.253x | -93.85% |
| 2017-12-31 | $-800.08K | $-3.30 Million | 4.122x | +68.34% |
| 2016-12-31 | $-1.45 Million | $-3.55 Million | 2.449x | +130.94% |
| 2015-12-31 | $471.00K | $-3.73 Million | -7.915x | -304.53% |
| 2014-12-31 | $-453.55K | $-1.76 Million | 3.870x | +873.40% |
| 2013-12-31 | $-36.46K | $-14.49K | 0.398x | +695.12% |
| 2012-12-31 | $38.56K | $1.93K | 0.050x | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more